Baqsimi

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Download Risalah maklumat (PIL)
05-07-2021
Download Ciri produk (SPC)
05-07-2021
Download Laporan Penilaian Awam (PAR)
06-02-2020

Bahan aktif:

Glucagon

Boleh didapati daripada:

Eli Lilly Nederland B.V.

Kod ATC:

H04AA01

INN (Nama Antarabangsa):

glucagon

Kumpulan terapeutik:

Pancreatic hormones, Glycogenolytic hormones

Kawasan terapeutik:

Diabetes Mellitus

Tanda-tanda terapeutik:

Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Ringkasan produk:

Revision: 1

Status kebenaran:

Authorised

Tarikh kebenaran:

2019-12-16

Risalah maklumat

                                23
B. PACKAGE LEAFLET
24
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
BAQSIMI 3 MG NASAL POWDER IN SINGLE-DOSE CONTAINER
glucagon
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Baqsimi is and what it is used for
2.
What you need to know before you are given Baqsimi
3.
How Baqsimi is given
4.
Possible side effects
5.
How to store Baqsimi
6.
Contents of the pack and other information
1.
WHAT BAQSIMI IS AND WHAT IT IS USED FOR
Baqsimi contains the active substance glucagon, which belongs to a
group of medicines called
glycogenolytic hormones. It is used to treat severe hypoglycaemia
(very low blood sugar) in people
with diabetes. It is for use in adults, adolescents, and children aged
4 years or older.
Glucagon is a natural hormone produced by the pancreas. It works in
the opposite way to insulin and
raises blood sugar. It does this by converting stored sugar in the
liver called glycogen to glucose (a
form of sugar that the body uses for energy). The glucose then enters
the bloodstream and raises the
blood sugar level, so reducing the effects of hypoglycaemia.
You should always carry Baqsimi with you and tell your friends and
family that you are carrying it.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN BAQSIMI
_ _
IMPORTANT INFORMATION
If you are at risk of severe hypoglycaemia you should always have
Baqsimi readily available:
-
show your family members, friends, or people you work with where you
keep this medicine and
explain when and how to use it. Delay in treatment may be harmful
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Baqsimi 3 mg nasal powder in single-dose container
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single-dose container delivers nasal powder with 3 mg of
glucagon.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Nasal powder in single-dose container (nasal powder).
White to practically white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Baqsimi is indicated for the treatment of severe hypoglycaemia in
adults, adolescents, and children
aged 4 years and over with diabetes mellitus.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults, adolescents and children aged 4 years and over _
The recommended dose is 3 mg glucagon administered into one nostril.
_Elderly _
(≥ 65 years)
_ _
No dose adjustment is required based on age.
Efficacy and safety data are very limited in patients aged 65 years
and absent in patients aged 75 and
above.
_ _
_Renal and hepatic impairment _
No dose adjustment is required based on renal and hepatic function.
_ _
_Paediatric population 0 - < 4 years _
The safety and efficacy of Baqsimi in infants and children aged 0 to <
4 years have not yet been
established. No data are available.
Method of administration
Nasal use only. Glucagon nasal powder is given in a single nostril.
Glucagon is passively absorbed
through the nasal mucosa. It is not necessary to inhale or breathe
deeply after dosing.
INSTRUCTIONS FOR ADMINISTERING GLUCAGON NASAL POWDER
1.
Remove the shrink wrap by pulling on the red stripe.
2.
Remove the single-dose container from the tube. Do not press the
plunger until ready to give the
dose.
3.
Hold the single-dose container between fingers and thumb. Do not test
before use as it contains
3
only one dose of glucagon and cannot be reused.
4.
Insert the tip of the single-dose container gently in one of the
nostrils until finger(s) touch the
outside of the nose.
5.
Push the plunger all the way in. The dose is complete when the green
line is no longer show
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 05-07-2021
Ciri produk Ciri produk Bulgaria 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 06-02-2020
Risalah maklumat Risalah maklumat Sepanyol 05-07-2021
Ciri produk Ciri produk Sepanyol 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 06-02-2020
Risalah maklumat Risalah maklumat Czech 05-07-2021
Ciri produk Ciri produk Czech 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Czech 06-02-2020
Risalah maklumat Risalah maklumat Denmark 05-07-2021
Ciri produk Ciri produk Denmark 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 06-02-2020
Risalah maklumat Risalah maklumat Jerman 05-07-2021
Ciri produk Ciri produk Jerman 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 06-02-2020
Risalah maklumat Risalah maklumat Estonia 05-07-2021
Ciri produk Ciri produk Estonia 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 06-02-2020
Risalah maklumat Risalah maklumat Greek 05-07-2021
Ciri produk Ciri produk Greek 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Greek 06-02-2020
Risalah maklumat Risalah maklumat Perancis 05-07-2021
Ciri produk Ciri produk Perancis 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 06-02-2020
Risalah maklumat Risalah maklumat Itali 05-07-2021
Ciri produk Ciri produk Itali 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Itali 06-02-2020
Risalah maklumat Risalah maklumat Latvia 05-07-2021
Ciri produk Ciri produk Latvia 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 06-02-2020
Risalah maklumat Risalah maklumat Lithuania 05-07-2021
Ciri produk Ciri produk Lithuania 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 06-02-2020
Risalah maklumat Risalah maklumat Hungary 05-07-2021
Ciri produk Ciri produk Hungary 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 06-02-2020
Risalah maklumat Risalah maklumat Malta 05-07-2021
Ciri produk Ciri produk Malta 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Malta 06-02-2020
Risalah maklumat Risalah maklumat Belanda 05-07-2021
Ciri produk Ciri produk Belanda 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 06-02-2020
Risalah maklumat Risalah maklumat Poland 05-07-2021
Ciri produk Ciri produk Poland 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Poland 06-02-2020
Risalah maklumat Risalah maklumat Portugis 05-07-2021
Ciri produk Ciri produk Portugis 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 06-02-2020
Risalah maklumat Risalah maklumat Romania 05-07-2021
Ciri produk Ciri produk Romania 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Romania 06-02-2020
Risalah maklumat Risalah maklumat Slovak 05-07-2021
Ciri produk Ciri produk Slovak 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 06-02-2020
Risalah maklumat Risalah maklumat Slovenia 05-07-2021
Ciri produk Ciri produk Slovenia 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 06-02-2020
Risalah maklumat Risalah maklumat Finland 05-07-2021
Ciri produk Ciri produk Finland 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Finland 06-02-2020
Risalah maklumat Risalah maklumat Sweden 05-07-2021
Ciri produk Ciri produk Sweden 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 06-02-2020
Risalah maklumat Risalah maklumat Norway 05-07-2021
Ciri produk Ciri produk Norway 05-07-2021
Risalah maklumat Risalah maklumat Iceland 05-07-2021
Ciri produk Ciri produk Iceland 05-07-2021
Risalah maklumat Risalah maklumat Croat 05-07-2021
Ciri produk Ciri produk Croat 05-07-2021
Laporan Penilaian Awam Laporan Penilaian Awam Croat 06-02-2020

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen